Salarius Announces Name And Ticker Change Following Decoy Therapeutics Combination; Adopting New NASDAQ Ticker DCOY

Salarius Pharmaceuticals has announced plans to change its corporate name to Decoy Therapeutics Inc. and adopt a new NASDAQ ticker symbol, DCOY, following the completion of its recent combination with Decoy Therapeutics Inc. The rebranding reflects the Company’s strategic transformation into a platform-driven biotechnology company focused on peptide-conjugate therapeutics targeting viral diseases and oncology.

The name and ticker symbol change are expected to take effect in early January 2026, with the Company continuing to trade under the symbol SLRX until that time. The transition will not affect business operations, shareholder ownership, or the Company’s transfer agent, and stockholder approval was not required. As previously disclosed, Decoy’s senior leadership team, together with Salarius’s finance organization, will lead the combined company.

Decoy Therapeutics is advancing a proprietary peptide-conjugate platform designed to selectively intercept and neutralize high-value biological targets. Early programs are focused on pan-coronavirus activity and multi-viral respiratory threats, including influenza and RSV. The Company’s lead antiviral program has already attracted strategic interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, positioning Decoy to pursue non-dilutive funding opportunities, collaborations, and future development partnerships as data mature.

“This planned rebrand reflects far more than a name change, it represents the strategic foundation of the combined companies,” said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. “With the merger complete, we are now singularly focused on advancing integration of Decoy’s differentiated therapeutic platforms, expanding our pipeline and creating multiple value-inflection opportunities through data generation, program advancements, including getting our lead program into human clinical trials.”

In parallel, the Company is expanding its discovery pipeline with next-generation programs, including multi-virus decoy candidates addressing overlapping respiratory infections, as well as cell-based and organoid-level validation of novel GPCR-targeted drug candidates beyond antivirals. These initiatives are intended to support multiple IND-enabling activities, peer-reviewed publications, and partnering discussions while maintaining capital efficiency.

Looking ahead to 2026, Decoy Therapeutics plans to focus on execution and data generation, advancing lead antiviral programs toward regulatory readiness, expanding preclinical validation across platforms, and leveraging AI-enabled computational infrastructure to accelerate candidate selection. The Company also aims to strengthen its capital structure, enhance investor visibility, and pursue strategic collaborations with pharmaceutical companies, technology partners, and academic institutions.

Decoy believes this execution-driven strategy positions the Company to pursue multiple high-value development opportunities while retaining long-term upside through partnerships and non-dilutive funding sources.